Compare MC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | HALO |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 7.4B |
| IPO Year | 2014 | N/A |
| Metric | MC | HALO |
|---|---|---|
| Price | $74.65 | $75.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $73.63 | $73.33 |
| AVG Volume (30 Days) | 772.9K | ★ 2.2M |
| Earning Date | 02-04-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 446.16 | 56.68 |
| EPS | 3.17 | ★ 4.74 |
| Revenue | ★ $1,467,580,000.00 | $1,242,852,000.00 |
| Revenue This Year | $27.08 | $34.83 |
| Revenue Next Year | $17.26 | $24.84 |
| P/E Ratio | $24.16 | ★ $15.44 |
| Revenue Growth | ★ 51.19 | 31.19 |
| 52 Week Low | $47.00 | $47.50 |
| 52 Week High | $82.89 | $79.50 |
| Indicator | MC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 64.24 | 72.04 |
| Support Level | $68.57 | $67.02 |
| Resistance Level | $71.78 | $69.48 |
| Average True Range (ATR) | 1.89 | 1.85 |
| MACD | 0.38 | 0.92 |
| Stochastic Oscillator | 73.71 | 91.07 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.